Accompanying therapy with autologous mobilized CD34 positive mononuclear cells to the patients who receive chemo- and radiotherapy
Diseases include: all oncological diseases that require chemo- or radiotherapy.
Therapy principle: The therapeutic protocols for most types of cancers imply chemotherapy or chemo- in combination with radiotherapy. Chemotherapy eliminates cancer cells (CCs) and at the same time negatively influences human health in general including healthy rapidly dividing cells and tissues of the organism. The bone marrow is the most susceptible as it regularly produces various cells of blood and immune system. As a result, 6 to 14 days of chemotherapy decrease the levels of the white blood cells (WBCs), platelets and red blood cells (RBCs). Every next course of the specific tumor treatment is followed by even more serious side effects leading to the onset of bad infections against the background of pathological changes of blood (leukopenia, anemia and thrombocytopenia) accompanied by the risk of hemorrhage, as well as the delay of the next course of chemotherapy or radiotherapy by 21 to 28 days and even more. However, it has been demonstrated that increased interval between the chemotherapy courses decreases its efficiency by 15% in the long run. The side effects are associated with an exhausted pool of the hematopoietic precursors contained by the mononuclear cells fraction. However, the mononuclear cells can be isolated from the peripheral blood in advance.
The harvest of the peripheral blood mononuclear cells (PBMCs) before the treatment or immediately during the very first courses of chemotherapy when the precursor cells have not been toxically affected yet, offers a solution to the problem and helps reduce the frequency and severity of the side effects. The PBMCs are provisionally mobilized by the recombinant cytokines and harvested by the cell separator with a disposable system. The surface membrane marker CD34+ of the isolated precursors is used to characterize the cells. The isolated autologous cells are cryopreserved in parts and later are transfused to the patient 24 to 48 hours after the end of the chemo- or radiotherapy to invigorate the restoration of the hematopoietic and immune systems and improve the survival rates of cancer patients.
The result. The number of life-threatening complications after chemo- radiotherapy reduces by more than 38.5%. And the courses of chemo- and radiotherapy can be administered regularly according to the schedule promoting efficiency of the cytotoxic and cytostatic therapy.
